
Health care accounts for 5 per cent of total global carbon emissions, and medical devices and technology are responsible for a large portion of that, according to Boston Consulting Groups (BCG). Much of this comes from the manufacturing operations and supply chains of medtech companies and their suppliers. At the provider level, MedTech generates tonnes of unrecycled waste through single-use disposable products and packaging.
Stringent regulations
Regulators worldwide are also establishing rules requiring companies to publish standardised ESG information. In Europe, regulations are already in place. In the US, proposed new disclosure requirements for public companies focus on climate-related risks and relevant risk management processes. Another key ESG trend is the mandatory sustainability reporting obligations imposed on companies globally. In the Asia-Pacific region, ESG regulation is accelerating due to the urgent need for greater transparency and tightened definitions for sustainable investment products. The twofold increase in the number of ESG policies in the region over the past five years has led to increased corporate ESG disclosure across most APAC markets, which now align with or exceed those in the US, says Goldman Sachs report.
The Australian government plans to introduce mandatory climate-related financial disclosure requirements, encouraging companies to adopt more environmentally responsible practices. Moreover, stringent waste disposal regulations are on the horizon, with Japan aiming to cut plastic waste by 25 per cent and South Korea by 50 per cent, both by 2030. In light of all this, the medtech industry and the broader healthcare sector are increasingly committing to environmental stewardship.
Cutting carbon footprints
هذه القصة مأخوذة من طبعة June 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة June 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول

Inventia announces groundbreaking advancement in 3D cell culture technology
Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.

Aphra names Justin Untersteiner as CEO
The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).

WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.

Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.

PanopticAI gets US FDA clearance for contactless vital signs monitoring software
PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.

Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.

Axel Klarmeyer joins as CEO at Chamlion International
China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.

World Bank supports Bosnia and Herzegovina in strengthening healthcare
The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).

GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.

NIH to lead implementation of National Plan to End Parkinson's Act in US
With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.